7.77 USD
-0.28 (-3.48%)
Overall GYRE gets a fundamental rating of 6 out of 10. We evaluated GYRE against 525 industry peers in the Biotechnology industry. While GYRE has a great health rating, its profitability is only average at the moment. GYRE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year GYRE was profitable.
- In the past year GYRE had a positive cash flow from operations.
- GYRE had negative earnings in 4 of the past 5 years.
- GYRE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- GYRE has a Return On Assets of 4.17%. This is amongst the best in the industry. GYRE outperforms 90.67% of its industry peers.
- GYRE's Return On Equity of 6.53% is amongst the best of the industry. GYRE outperforms 90.86% of its industry peers.
- GYRE's Return On Invested Capital of 6.46% is amongst the best of the industry. GYRE outperforms 92.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.17% | ||
| ROE | 6.53% | ||
| ROIC | 6.46% |
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of GYRE (6.20%) is better than 90.29% of its industry peers.
- Looking at the Operating Margin, with a value of 11.22%, GYRE belongs to the top of the industry, outperforming 92.00% of the companies in the same industry.
- GYRE has a Gross Margin of 95.48%. This is amongst the best in the industry. GYRE outperforms 95.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.22% | ||
| PM (TTM) | 6.2% | ||
| GM | 95.48% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GYRE is destroying value.
- The number of shares outstanding for GYRE has been increased compared to 1 year ago.
- The number of shares outstanding for GYRE has been increased compared to 5 years ago.
- There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- GYRE has an Altman-Z score of 8.63. This indicates that GYRE is financially healthy and has little risk of bankruptcy at the moment.
- GYRE has a Altman-Z score of 8.63. This is in the better half of the industry: GYRE outperforms 79.62% of its industry peers.
- There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.63 |
ROIC/WACC0.73
WACC8.9%
2.3 Liquidity
- GYRE has a Current Ratio of 6.19. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 6.19, GYRE is in the better half of the industry, outperforming 63.43% of the companies in the same industry.
- GYRE has a Quick Ratio of 5.64. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
- GYRE has a better Quick ratio (5.64) than 60.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.19 | ||
| Quick Ratio | 5.64 |
3. Growth
3.1 Past
- GYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 128.26%, which is quite impressive.
- Looking at the last year, GYRE shows a very negative growth in Revenue. The Revenue has decreased by -43.94% in the last year.
- The Revenue has been growing by 143.34% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)128.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.39%
Revenue 1Y (TTM)-43.94%
Revenue growth 3Y143.34%
Revenue growth 5YN/A
Sales Q2Q%19.92%
3.2 Future
- The Earnings Per Share is expected to grow by 16.75% on average over the next years. This is quite good.
- The Revenue is expected to grow by 17.78% on average over the next years. This is quite good.
EPS Next Y-51.43%
EPS Next 2Y-22.25%
EPS Next 3Y-39.03%
EPS Next 5Y16.75%
Revenue Next Year-3.9%
Revenue Next 2Y10.17%
Revenue Next 3Y6.96%
Revenue Next 5Y17.78%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 59.77, GYRE can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, GYRE is valued cheaply inside the industry as 90.86% of the companies are valued more expensively.
- GYRE's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.30.
- With a Price/Forward Earnings ratio of 40.81, GYRE can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, GYRE is valued cheaper than 91.24% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of GYRE to the average of the S&P500 Index (24.32), we can say GYRE is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 59.77 | ||
| Fwd PE | 40.81 |
4.2 Price Multiples
- 91.24% of the companies in the same industry are more expensive than GYRE, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, GYRE is valued cheaper than 89.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 523.51 | ||
| EV/EBITDA | 45.46 |
4.3 Compensation for Growth
- GYRE's earnings are expected to decrease with -39.03% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.25%
EPS Next 3Y-39.03%
5. Dividend
5.1 Amount
- GYRE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
GYRE THERAPEUTICS INC / GYRE FAQ
What is the fundamental rating for GYRE stock?
ChartMill assigns a fundamental rating of 6 / 10 to GYRE.
Can you provide the valuation status for GYRE THERAPEUTICS INC?
ChartMill assigns a valuation rating of 4 / 10 to GYRE THERAPEUTICS INC (GYRE). This can be considered as Fairly Valued.
Can you provide the profitability details for GYRE THERAPEUTICS INC?
GYRE THERAPEUTICS INC (GYRE) has a profitability rating of 5 / 10.
What is the valuation of GYRE THERAPEUTICS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for GYRE THERAPEUTICS INC (GYRE) is 59.77 and the Price/Book (PB) ratio is 6.93.
What is the earnings growth outlook for GYRE THERAPEUTICS INC?
The Earnings per Share (EPS) of GYRE THERAPEUTICS INC (GYRE) is expected to decline by -51.43% in the next year.